Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01474512
Registration number
NCT01474512
Ethics application status
Date submitted
15/11/2011
Date registered
18/11/2011
Date last updated
3/10/2019
Titles & IDs
Public title
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
Query!
Scientific title
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Query!
Secondary ID [1]
0
0
I1F-MC-RHAZ
Query!
Secondary ID [2]
0
0
12972
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
UNCOVER-1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Psoriasis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Treatment: Drugs - Placebo
Experimental: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) - Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 \[every 2 weeks (Q2W)\] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 \[every 4 weeks (Q4W)\] or Dosing Regimen 3 \[every 12 weeks Q12W)\].
Experimental: 80 mg Ixekizumab Dosing Regimen 2 (Q4W) - Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
Experimental: 80 mg Ixekizumab Dosing Regimen 3 (Q12W) - Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
Placebo comparator: Placebo - Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
Treatment: Drugs: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Administered SC
Treatment: Drugs: Placebo
Administered SC
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)
Query!
Assessment method [1]
0
0
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Query!
Timepoint [1]
0
0
Week 12
Query!
Primary outcome [2]
0
0
Percentage of Participants Achieving =75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)
Query!
Assessment method [2]
0
0
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of =75% in the PASI score compared to baseline.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)
Query!
Assessment method [1]
0
0
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)
Query!
Assessment method [2]
0
0
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of =90% or of 100% respectively in PASI scores compared to baseline.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period
Query!
Assessment method [3]
0
0
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
Query!
Timepoint [3]
0
0
Week 60
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score =4 Point Reduction From Baseline
Query!
Assessment method [4]
0
0
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
Query!
Timepoint [4]
0
0
Baseline, Week 12
Query!
Secondary outcome [5]
0
0
Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score
Query!
Assessment method [5]
0
0
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).
Query!
Timepoint [5]
0
0
Baseline, Week 12
Query!
Secondary outcome [6]
0
0
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
Query!
Assessment method [6]
0
0
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.
Query!
Timepoint [6]
0
0
Baseline, Week 12
Query!
Secondary outcome [7]
0
0
Percent of Body Surface Area (BSA) Involvement of Ps
Query!
Assessment method [7]
0
0
BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.
Query!
Timepoint [7]
0
0
Week 12
Query!
Secondary outcome [8]
0
0
Change From Baseline in Psoriasis Scalp Severity Index (PSSI)
Query!
Assessment method [8]
0
0
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.
Query!
Timepoint [8]
0
0
Baseline, Week 12
Query!
Secondary outcome [9]
0
0
Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes (PRO)
Query!
Assessment method [9]
0
0
WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).
Query!
Timepoint [9]
0
0
Baseline, Week 12
Query!
Secondary outcome [10]
0
0
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)
Query!
Assessment method [10]
0
0
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.
Query!
Timepoint [10]
0
0
Baseline, Week 12
Query!
Secondary outcome [11]
0
0
Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)
Query!
Assessment method [11]
0
0
The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.
Query!
Timepoint [11]
0
0
Baseline, Week 12
Query!
Secondary outcome [12]
0
0
Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)
Query!
Assessment method [12]
0
0
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.
Query!
Timepoint [12]
0
0
Baseline, Week 12
Query!
Secondary outcome [13]
0
0
Percentage of Participants Achieving Palmoplantar PASI (PPASI) of =50% (PPASI50), =75% (PPASI75), or 100% (PPASI100) Improvement
Query!
Assessment method [13]
0
0
The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation \[scores range from 0 (none) to 4 (very severe) for each\] multiplied by the score for the extent of palm and sole area involvement \[scores range from 0 (0%) to 6 (90 to100%)\], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.
Query!
Timepoint [13]
0
0
Week 12
Query!
Secondary outcome [14]
0
0
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Weeks 12: Day 84 and Week 24: Day 168
Query!
Secondary outcome [15]
0
0
Percentage of Participants With Anti-ixekizumab Antibodies
Query!
Assessment method [15]
0
0
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Query!
Timepoint [15]
0
0
Baseline through Week 12
Query!
Eligibility
Key inclusion criteria
* Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization
* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization
* Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization
* Candidate for phototherapy and/or systemic therapy
* Men must agree to use a reliable method of birth control during the study
* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Pustular, erythrodermic, and/or guttate forms of psoriasis
* History of drug-induced psoriasis
* Clinically significant flare of psoriasis during the 12 weeks prior to randomization
* Concurrent or recent use of any biologic agent
* Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization
* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study
* Have participated in any study with interleukin (IL)-17 antagonists, including LY2439821
* Serious disorder or illness other than plaque psoriasis
* Serious infection within the last 3 months
* Breastfeeding or nursing (lactating) women.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/11/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/09/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1296
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kogarah
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Benowa
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Woolloogabba
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Carlton
Query!
Recruitment hospital [6]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville
Query!
Recruitment hospital [7]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
4217 - Benowa
Query!
Recruitment postcode(s) [3]
0
0
4120 - Woolloogabba
Query!
Recruitment postcode(s) [4]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [6]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [7]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Rhode Island
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Utah
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Washington
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
British Columbia
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Manitoba
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
New Brunswick
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Nova Scotia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Aarhus
Query!
Country [27]
0
0
Denmark
Query!
State/province [27]
0
0
Hellerup
Query!
Country [28]
0
0
Denmark
Query!
State/province [28]
0
0
Kobenhavn
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Berlin
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Darmstadt
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Frankfurt
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Hamburg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Hanau
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Hannover
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Kiel
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Köln
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Mahlow
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Mainz
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Münster
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Quedlinburg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Wuppertal
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Budapest
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Debrecen
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Miskolc
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Szeged
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Szolnok
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Szombathely
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Bergamo
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Bologna
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Padova
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Pisa
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Aichi
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Fukuoka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Kochi
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Kyoto
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Shiga
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Shizuoka
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Tochigi
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Tokyo
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Bialystok
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Elblag
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Krakow
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lodz
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Lublin
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Szczecin
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Torun
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Warsaw
Query!
Country [68]
0
0
Romania
Query!
State/province [68]
0
0
Baia Mare
Query!
Country [69]
0
0
Romania
Query!
State/province [69]
0
0
Bucharest
Query!
Country [70]
0
0
Romania
Query!
State/province [70]
0
0
Craiova
Query!
Country [71]
0
0
Romania
Query!
State/province [71]
0
0
Iasi
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Manchester
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
North Lincolnshire
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
Scotland
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Warwickshire
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Lanarkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01474512
Query!
Trial related presentations / publications
Elewski BE, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Dermatol Ther (Heidelb). 2022 Apr;12(4):911-920. doi: 10.1007/s13555-022-00704-2. Epub 2022 Mar 13. Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, Gooderham M, Ferris LK, Griffiths CEM, ElMaraghy H, Crane H, Patel H, Burge R, Gallo G, Shrom D, Leung A, Lin CY, Papp K. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. doi: 10.1007/s13555-020-00367-x. Epub 2020 Mar 21. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. Armstrong AW, Lynde CW, McBride SR, Stahle M, Edson-Heredia E, Zhu B, Amato D, Nikai E, Yang FE, Gordon KB. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 Jun 1;152(6):661-9. doi: 10.1001/jamadermatol.2016.0269.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01474512
Download to PDF